💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Sunesis Pharma down 42% on extended timeline for vecabrutinib dose-escalation study

Published 03/09/2018, 11:15 AM
© Reuters.  Sunesis Pharma down 42% on extended timeline for vecabrutinib dose-escalation study
VIRX
-
  • Investors are punishing Sunesis Pharmaceuticals (SNSS -42.4%) for its delay in determining the recommended Phase 2 dose for BTK-inhibitor vecabrutinib in adults patients with chronic lymphocytic leukemia (CLL) and other B cell cancers. The company says it expects the results from the dose-ranging Phase 1b study to be completed in the fall, about three months later than expected.
  • In its Q4 conference call, interim CEO Dayton Misfeldt said they will expand the 50 mg cohort to six patients after one participant progressed after completing the first treatment cycle and another experienced a dose-limiting toxicity. As a result, it will not present preliminary data at a medical meeting next quarter.
  • Now read: KemPharm: What Now After FDA Approval?


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.